Affiliation:
1. Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital Capital Medical University Beijing China
2. Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital Peking University Ninth School of Clinical Medicine Beijing China
3. Department of Surgical Oncology, Beijing Tsinghua Changgung Hospital Tsinghua University Beijing China
Abstract
AbstractMalignant peritoneal mesothelioma (MPM) is a rare and invasive tumor, and some patients will develop paraneoplastic syndrome (PS) during the course of the disease. This review summarizes PS associated with MPM, focusing on the clinical characteristics and treatment progress in hematological, endocrine, rheumatic, neurological, urinary, and other systems to decrease missed diagnosis and misdiagnosis, help early diagnosis and prompt treatment, and provide guidance for the clinical decision‐making of this kind of patients.